TLR based therapeutics

被引：88

作者：

Dunne, Aisling

Marshall, Neil A.

Mills, Kingston H. G. ^{[1
]}

机构：

[1] Trinity Coll Dublin, Sch Biochem & Immunol, Dublin, Ireland

来源：

CURRENT OPINION IN PHARMACOLOGY | 2011年 / 11卷 / 04期

基金：

爱尔兰科学基金会;

关键词：

REGULATORY T-CELLS; TOLL-LIKE RECEPTORS; INFLAMMATION-ASSOCIATED CANCER; LOW-DOSE CYCLOPHOSPHAMIDE; IMMUNE-RESPONSE MODIFIER; BACILLUS-CALMETTE-GUERIN; NF-KAPPA-B; DENDRITIC CELLS; CYCLOOXYGENASE-2; EXPRESSION; METASTATIC MELANOMA;

D O I：

10.1016/j.coph.2011.03.004

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Toll-like receptors (TLRs) play a crucial role in innate immune responses to infection. Binding of agonists to TLRs promotes maturation of antigen presenting cells, such as dendritic cells, which in turn directs the induction of adaptive immune responses. For this reason TLR agonists are being exploited as vaccine adjuvants for infectious disease or cancer and as therapeutics against tumors. However TLR agonists also promote inflammatory cytokine production and have a pathogenic role in many diseases with an inflammatory basis, including autoimmune diseases. Consequently, antibodies to TLRs and inhibitors of TLR signalling pathways have considerable potential as therapeutics for inflammatory disorders. Some have shown to be efficacious in pre-clinical models, and have now entered clinical trials.

引用

收藏

页码：404 / 411

页数：8

相关论文

共 82 条

[1]

Toll-like receptor agonists in cancer therapy [J].

Adams, Sylvia .

IMMUNOTHERAPY, 2009, 1 (06) :949-964

[2]

Myocardial Ischemia/Reperfusion Injury Is Mediated by Leukocytic Toll-Like Receptor-2 and Reduced by Systemic Administration of a Novel Anti-Toll-Like Receptor-2 Antibody [J].

Arslan, Fatih ;

Smeets, Mirjam B. ;

O'Neill, Luke A. J. ;

Keogh, Brian ;

McGuirk, Peter ;

Timmers, Leo ;

Tersteeg, Claudia ;

Hoefer, Imo E. ;

Doevendans, Pieter A. ;

Pasterkamp, Gerard ;

de Kleijn, Dominique P. V. .

CIRCULATION, 2010, 121 (01) :80-90

[3]

Tumour-derived prostaglandin E2 and transforming growth factor-β synergize to inhibit plasmacytoid dendritic cell-derived interferon-α [J].

Bekeredjian-Ding, Isabelle ;

Schafer, Meike ;

Hartmann, Evelyn ;

Pries, Ralph ;

Parcina, Marijo ;

Schneider, Philip ;

Giese, Thomas ;

Endres, Stefan ;

Wollenberg, Barbara ;

Hartmann, Gunther .

IMMUNOLOGY, 2009, 128 (03) :439-450

[4]

A Phase II, double-blind, placebo-controlled, ascending-dose study of eritoran (E5564), a lipid a antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass [J].

Bennett-Guerrero, Elliott ;

Grocott, Hilary P. ;

Levy, Jerrold H. ;

Stierer, Kevin A. ;

Hogue, Charles W. ;

Cheung, Albert T. ;

Newman, Mark F. ;

Carter, Alison A. ;

Rossignol, Daniel P. ;

Collard, Charles D. .

ANESTHESIA AND ANALGESIA, 2007, 104 (02) :378-383

[5]

Bickels J, 2002, ISRAEL MED ASSOC J, V4, P471

[6]

Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study [J].

Bogdahn, U. ;

Hau, P. ;

Stockhammer, G. ;

Venkataramana, N. K. ;

Mahapatra, A. K. ;

Suri, A. ;

Balasubramaniam, A. ;

Nair, S. ;

Oliushine, V. ;

Parfenov, V. ;

Poverennova, I. ;

Zaaroor, M. ;

Jachimczak, P. ;

Ludwig, S. ;

Schmaus, S. ;

Heinrichs, H. ;

Schlingensiepen, K-H .

NEURO-ONCOLOGY, 2011, 13 (01) :132-142

[7]

Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma [J].

Bong, AB ;

Bonnekoh, B ;

Franke, I ;

Schön, MP ;

Ulrich, J ;

Gollnick, H .

DERMATOLOGY, 2002, 205 (02) :135-138

[8]

Locally Administered TLR7 Agonists Drive Systemic Antitumor Immune Responses That Are Enhanced by Anti-CD40 Immunotherapy [J].

Broomfield, Steve A. ;

van der Most, Robbert G. ;

Prosser, Amy C. ;

Mahendran, Sathish ;

Tovey, Michael G. ;

Smyth, Mark J. ;

Robinson, Bruce W. S. ;

Currie, Andrew J. .

JOURNAL OF IMMUNOLOGY, 2009, 182 (09) :5217-5224

[9]

Phenotypic, functional and molecular analysis of lymphocytes associated with bladder cancer [J].

Bruno, S ;

Machi, AM ;

Semino, C ;

Meta, M ;

Ponte, M ;

Varaldo, M ;

Curotto, A ;

Ferlazzo, G ;

Decensi, A ;

Melioli, G .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 1996, 42 (01) :47-54

[10]

Cannon MJ, 2011, EXPERT OPIN BIOL THE

← 1 2 3 4 5 6 7 8 9 →